R&D News | pharmaphorum

News

Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.

News

Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.

News

Kaken has revealed the data that supported its recent marketing application for serabelisib as a treatment for vascular malformations in Japan.

News

Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.

News

Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in sickle cell disease.

News

Faced with the prospect of running out of cash, Jasper Therapeutics has merged with Kira Pharma, fortified by $132m in new private funding.